Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: An overview of Cochrane reviews

Evidence-Based Child Health

Volumn 8, Issue 6, 2013, Pages 2063-2075

  Harrold, J ^a   Ali, S ^b   Oleszczuk, M ^b   Lacaze Masmonteil, T ^a   Hartling, L ^c  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Corticosteroids; Infants; Neonates; Preterm

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE; HYDROCORTISONE; MOMETASONE FUROATE; PLACEBO; SURFACTANT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTIFICIAL VENTILATION; BAYLEY II MENTAL DEVELOPMENTAL INDEX; CEREBRAL PALSY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFANT MORTALITY; LOW DRUG DOSE; LUNG DYSPLASIA; MORBIDITY; OUTCOME ASSESSMENT; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENTAL INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84888019244     PISSN: None     EISSN: 15576272     Source Type: Journal    
DOI: 10.1002/ebch.1955     Document Type: Article

References (42)

1. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116: 1353-1360.
2. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine 2001; 163: 1723-1729. Epub June 13, 2001.
3. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease-Bronchopulmonary dysplasia. The New England Journal of Medicine 1967; 276: 357-368.
4. Greenough A. Prenatal factors in the development of chronic lung disease. Seminars in Fetal and Neonatal Medicine 2009; 14: 339-344.
5. Merritt TA, Deming DD, Boynton BR. The 'new' bronchopulmonary dysplasia: Challenges and commentary. Seminars in Fetal and Neonatal Medicine 2009; 14: 345-357.
6. Philip AGS. Chronic lung disease of prematurity: A short history. Seminars in Fetal and Neonatal Medicine 2009; 14: 333-338.
7. Askie LM, Ballard RA, Cutter G, Dani C, Elbourne D, Field D, et al. Inhaled nitric oxide in preterm infants: A systematic review and individual patient data meta-analysis. BMC Pediatrics 2010; 10: 15.
8. Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: Clinical presentation. The Journal of Pediatrics 1979; 95(5 Pt 2): 819-823. Epub November 1, 1979.
9. Walsh MC, Wilson-Costello D, Zadell A, Newman N, Fanaroff A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. Journal of Perinatology : Official Journal of the California Perinatal Association 2003; 23: 451-456. Epub September 19, 2003.
10. Kramer BW, Lievense S, Been JV, Zimmermann LJ. From classic to new bronchopulmonary dysplasia [Van klassieke naar nieuwe bronchopulmonale dysplasie[. Nederlands tijdschrift voor geneeskunde 2010; 154: A1024. Epub May 12, 2010.
11. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. American Journal of Obstetrics and Gynecology 2007; 196: 147 e1-147 e8. Epub February 20, 2007.
12. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126: 443-456. Epub August 25, 2010.
13. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature-infants-Prediction from oxygen requirement in the neonatal-period. Pediatrics 1988; 82: 527-532.
14. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics 2001; 107: e1.
15. Doyle LW, Anderson PJ. Long-term outcomes of bronchopulmonary dysplasia. Seminars in Fetal and Neonatal Medicine 2009; 14: 391-395.
16. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: A systematic review. Neonatology 2010; 98: 289-296.
17. Gupta S, Prasanth K, Chen CM, Yeh TF. Postnatal corticosteroids for prevention and treatment of chronic lung disease in the preterm newborn. International Journal of Pediatrics 2012; 2012: 315642. Epub November 19, 2011.
18. Ryan RM, Ahmed Q, Lakshminrusimha S. Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia. Clinical Reviews in Allergy & Immunology 2008; 34: 174-190. Epub March 12, 2008.
19. Speer CP. Inflammation and bronchopulmonary dysplasia: a continuing story. Seminars in Fetal and Neonatal Medicine 2006; 11: 354-362. Epub May 17, 2006.
20. Kallapur SG, Jobe AH. Contribution of inflammation to lung injury and development. Archives of Disease in Childhood. Fetal and Neonatal Edition 2006; 91: F132-F135. Epub February 24, 2006.
21. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-New mechanisms for old drugs. The New England Journal of Medicine 2005; 353: 1711-1723.
22. Laughon MM, Smith PB, Bose C. Prevention of bronchopulmonary dysplasia. Seminars in Fetal and Neonatal Medicine 2009; 14: 374-382.
23. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nature Medicine 2002; 8: 473-479. Epub May 2, 2002.
24. Jarreau PH, Fayon M, Baud O, Autret-Leca E, Danan M, de Verdelhan A, et al. The use of postnatal corticosteroid therapy in premature infants to prevent or treat bronchopulmonary dysplasia: Current situation and recommendations. Archives de Pediatrie 2010; 17: 1480-1487.
25. Blackmon LR, Bell EF, Engle WA, Kanto WP, Martin GI, Miller CA, et al. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002; 109: 330-338.
26. Watterberg KL, Papile LA, Adamkin DH, Baley JE, Bhutani VK, Carlo WA, et al. Policy statement-postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2010; 126: 800-808.
27. Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Paediatrics & Child Health 2002; 7: 20-46. Epub 1 January, 2002.
28. Jefferies AL, Soc CP, Soc CP, Comm FN. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Paediatrics & Child Health 2012; 17: 573.
29. Shinwell ES, Eventov-Friedman S. Impact of perinatal corticosteroids on neuromotor development and outcome: Review of the literature and new meta-analysis. Seminars in Fetal and Neonatal Medicine 2009; 14: 164-170.
30. Yates HL, Newell SJ. Postnatal intravenous steroids and long-term neurological outcome: Recommendations from meta-analyses. Archives of Disease in Childhood: Fetal & Neonatal 2012; 97: F299-F303.
31. Onland W, Offringa M, van Kaam A. Late (>=7days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews 2012; 4: CD002311.
32. Halliday HL, Ehrenkranz RA, Doyle LW. Late (>7days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2009; 1: CD001145.
33. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2003; 1: CD001144. Epub January 22, 2003.
34. Halliday HL, Ehrenkranz RA, Doyle LW. Early (<8days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2010; 1: CD001146. Epub January 22, 2003.
35. Shah VS, Ohlsson A, Halliday HL, Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2012; 5: CD001969.
36. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2012; 5: CD002058.
37. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database of Systematic Reviews 2012; 5: CD002057.
38. McQuay HJ. Moore. Using numerical results from systematic reviews in clinical practice. Annals of Internal Medicine 1997; 126: 712-720.
39. Han S, Yu Z, Guo X, Dong X, Soll R. Intratracheal instillation of corticosteroids using surfactant as a vehicle for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome. Cochrane Database of Systematic Reviews 2011: protocol.
40. Thebaud B, Lacaze-Masmonteil T, Watterberg K. Postnatal glucocorticoids in very preterm infants: "The good, the bad, and the ugly"? Pediatrics 2001; 107: 413-415.
41. Onland W, Offringa M, De Jaegere AP, van Kaam AH. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics 2009; 123: 367-77. Epub January 2, 2009.
42. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB. Outcome at 2years of age of infants from the DART study: A multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics 2007; 119: 716-721.